In the News

October 27, 2016

Are cancer drugs worth the cost? That’s the question a controversial Boston-based non-profit, the Institute for Clinical and Economic Review (ICER), convened about last week in St. Louis to discuss. The group, who notoriously “cherry-picks data,” often reviews new medications, deems them too...

October 20, 2016

Ahead of an ICER meeting to review evidence and vote on cost-effectiveness ratings for non-small cell lung cancer treatments, a group of oncologists is airing “serious concerns” about the organization’s assessment techniques. The docs have laid out principles that they believe should serve as the “...

October 19, 2016

By Lee Schwartzberg, MD, David Ettinger, MD, Mohammad Jahanzeb, MD, Gregory Otterson, MD and David Waterhouse, MD   In the past year, Value Frameworks have been introduced as potential tools for policy-setting and decision-making in oncology by organizations including ASCO, NCCN, and ICER. We...

October 18, 2016

Originally published in the St. Louis Post-Dispatch | October 18, 2016 Having just hosted the latest of a decades-long string of presidential debates, St. Louis is rightfully proud of serving as a setting for vital national conversations. On Oct. 20, the Gateway City will be the site of another...

September 29, 2016

“Value” — especially in the context of healthcare and medicine — is a word that gets used so often these days, and in so many different ways, that it can be difficult to pin down exactly what it means – or should mean. In the debate over the value of prescription medicines, a recent proliferation...

Pages

IN THE NEWS

Mexico has been granted with the honor of hosting the #VIIWFER thanks to the support of #ARIAE the regional associa… https://t.co/0eFafofNg9

10 hours ago t.co/ICERWATCH/..

RT @wfer2018: Did you know #ICER is the biggest association of regulatory authorities with more than 200 members worldwide? #VIIWFER

16 hours ago t.co/ICERWATCH/..